Phase 2 N=59 A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants With Treatment-Emergent Adverse Events — 9; 8; 10; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=203 Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream
Dentin Sensitivity
Primary: Percentage Change From Baseline in VAS (Visual Analog Scale) With Air Stimulation — -51.44; -51.59; -41.59; -38.64 percentage change from baseline
N/A N=33 Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Graft Versus Host Disease
Primary: Rate of Grade 1 Upper GI and/or 2-4 Lower GI aGVHD Assessed Using CIBMTR Scoring — 10; 4 Participants
Phase 2 N=39 Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165 — 0.972; 13.799; 0.960…
Phase 4 N=188 SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline (on PGA) in Diurnal IOP (Mean of 09:00 and 11:00 Time Points) at Week 6 — -5.6; -2.1 mmHg — p=< 0.001
N/A N=35 Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
Essential Hypertension
Primary: The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy — 16; 8; 4 Participants
Phase 2 N=87 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Phase 1 N=36 Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Advanced Solid Tumors · Relapsed/Refractory Lymphoma
Primary: Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib — 17.3; 28.1; 18.5 nmol/L
Phase 4 N=36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Baseline (Day 0) — 2.53; 3.08; 2.61; 2.5 units on a scale
Phase 2 N=58 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants
Phase 2 N=245 A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Relapsing-Remitting Multiple Sclerosis
Primary: Total Number of Gd-Enhancing T1-Weighted MRI Lesions Per Scan Averaged During Weeks 12, 16, 20, and 24 — 1.819; 0.710; 1.237; 1.477 lesions per scan
Phase 2 N=291 A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
Osteo Arthritis Knee
Primary: Daily "Average Pain Over the Last 24 Hours" Score at Week 4 — 5.9; 5.9; 6.1; 5.9 score on a scale
N/A N=136 How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?
Glaucoma Diagnosis
Primary: Visual Evoked Potential (VEP) — 6.7; 7.1; 4.1 microvolts (uV) (amplitude)
Phase 4 N=82 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
Growth Hormone Deficiency
Primary: Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1 — 3.7 percentage of participants
Phase 3 N=41 Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.
Pain, Postoperative
Primary: Pain Reported on the Visual Analogue Scale (VAS) at 30 Minutes Postoperative — 5.7; 3.2 VAS scale 0-10